The stock of GlycoMimetics Inc (GLYC) has seen a 6.60% increase in the past week, with a 21.66% gain in the past month, and a 70.99% flourish in the past quarter. The volatility ratio for the week is 7.91%, and the volatility levels for the past 30 days are at 9.03% for GLYC. The simple moving average for the last 20 days is 9.11% for GLYC stock, with a simple moving average of -22.81% for the last 200 days.
Is It Worth Investing in GlycoMimetics Inc (NASDAQ: GLYC) Right Now?
Moreover, the 36-month beta value for GLYC is 1.81. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GLYC is 57.07M and currently, short sellers hold a 3.92% of that float. On January 31, 2025, GLYC’s average trading volume was 2.02M shares.
GLYC) stock’s latest price update
The stock of GlycoMimetics Inc (NASDAQ: GLYC) has increased by 13.86 when compared to last closing price of 0.25. Despite this, the company has experienced a 6.60% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-12 that Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ — Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.
Analysts’ Opinion of GLYC
CapitalOne, on the other hand, stated in their research note that they expect to see GLYC reach a price target of $12. The rating they have provided for GLYC stocks is “Overweight” according to the report published on December 22nd, 2023.
Jefferies gave a rating of “Buy” to GLYC, setting the target price at $4 in the report published on November 12th of the previous year.
GLYC Trading at 3.22% from the 50-Day Moving Average
After a stumble in the market that brought GLYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.71% of loss for the given period.
Volatility was left at 9.03%, however, over the last 30 days, the volatility rate increased by 7.91%, as shares surge +15.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.99% lower at present.
During the last 5 trading sessions, GLYC rose by +6.60%, which changed the moving average for the period of 200-days by -88.02% in comparison to the 20-day moving average, which settled at $0.2636. In addition, GlycoMimetics Inc saw 15.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLYC starting from Invus Public Equities, L.P., who sale 260,873 shares at the price of $0.19 back on Aug 08 ’24. After this action, Invus Public Equities, L.P. now owns 6,317,565 shares of GlycoMimetics Inc, valued at $50,009 using the latest closing price.
Invus Public Equities, L.P., the 10% Owner of GlycoMimetics Inc, sale 61,488 shares at $0.18 during a trade that took place back on Aug 07 ’24, which means that Invus Public Equities, L.P. is holding 6,578,438 shares at $11,197 based on the most recent closing price.
Stock Fundamentals for GLYC
Current profitability levels for the company are sitting at:
- -4229.75 for the present operating margin
- -4.03 for the gross margin
The net margin for GlycoMimetics Inc stands at -3973.54. The total capital return value is set at -3.72. Equity return is now at value -137.20, with -115.34 for asset returns.
Based on GlycoMimetics Inc (GLYC), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -133.56. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -72.68.
Currently, EBITDA for the company is -39.12 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 441.61. The receivables turnover for the company is 0.2for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
To wrap up, the performance of GlycoMimetics Inc (GLYC) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
